vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Nomad Foods Ltd (NOMD). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $834.9M, roughly 1.1× Nomad Foods Ltd). On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -2.6%). Nomad Foods Ltd produced more free cash flow last quarter ($272.4M vs $-6.0M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Nomad Foods is the largest frozen food company in Europe, whose popular brands include Birds Eye, Ledo, Iglo, Findus, and Frikom. The company manufactures, sells and distributes a range of frozen food products across 22 European markets, with its headquarters in the United Kingdom. The most popular products in Nomad Foods’ portfolio include fish fingers, creamed spinach, peas and chicken. Nomad Foods is listed on the New York Stock Exchange trading under the ticker “NOMD”.

ASTH vs NOMD — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.1× larger
ASTH
$950.5M
$834.9M
NOMD
Growing faster (revenue YoY)
ASTH
ASTH
+45.4% gap
ASTH
42.9%
-2.6%
NOMD
More free cash flow
NOMD
NOMD
$278.3M more FCF
NOMD
$272.4M
$-6.0M
ASTH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
NOMD
NOMD
Revenue
$950.5M
$834.9M
Net Profit
$6.6M
Gross Margin
25.6%
Operating Margin
1.9%
9.1%
Net Margin
0.7%
Revenue YoY
42.9%
-2.6%
Net Profit YoY
184.4%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
NOMD
NOMD
Q4 25
$950.5M
$834.9M
Q3 25
$956.0M
Q2 25
$654.8M
Q1 25
$620.4M
Q4 24
$665.2M
$856.9M
Q3 24
$478.7M
Q2 24
$486.3M
Q1 24
$404.4M
Net Profit
ASTH
ASTH
NOMD
NOMD
Q4 25
$6.6M
Q3 25
$373.0K
Q2 25
$9.4M
Q1 25
$6.7M
Q4 24
$-7.8M
$55.5M
Q3 24
$16.1M
Q2 24
$19.2M
Q1 24
$14.8M
Gross Margin
ASTH
ASTH
NOMD
NOMD
Q4 25
25.6%
Q3 25
Q2 25
Q1 25
Q4 24
28.5%
Q3 24
Q2 24
Q1 24
Operating Margin
ASTH
ASTH
NOMD
NOMD
Q4 25
1.9%
9.1%
Q3 25
2.0%
Q2 25
3.1%
Q1 25
3.3%
Q4 24
0.1%
11.5%
Q3 24
5.9%
Q2 24
6.2%
Q1 24
7.5%
Net Margin
ASTH
ASTH
NOMD
NOMD
Q4 25
0.7%
Q3 25
0.0%
Q2 25
1.4%
Q1 25
1.1%
Q4 24
-1.2%
6.5%
Q3 24
3.4%
Q2 24
3.9%
Q1 24
3.7%
EPS (diluted)
ASTH
ASTH
NOMD
NOMD
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
NOMD
NOMD
Cash + ST InvestmentsLiquidity on hand
$429.5M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$779.3M
$2.7B
Total Assets
$2.2B
$6.8B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
NOMD
NOMD
Q4 25
$429.5M
Q3 25
$463.4M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Total Debt
ASTH
ASTH
NOMD
NOMD
Q4 25
$2.5B
Q3 25
Q2 25
Q1 25
Q4 24
$2.4B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ASTH
ASTH
NOMD
NOMD
Q4 25
$779.3M
$2.7B
Q3 25
$775.5M
Q2 25
$765.5M
Q1 25
$745.4M
Q4 24
$712.7M
$2.9B
Q3 24
$704.6M
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
ASTH
ASTH
NOMD
NOMD
Q4 25
$2.2B
$6.8B
Q3 25
$2.2B
Q2 25
$1.4B
Q1 25
$1.3B
Q4 24
$1.4B
$6.9B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.2B
Debt / Equity
ASTH
ASTH
NOMD
NOMD
Q4 25
0.92×
Q3 25
Q2 25
Q1 25
Q4 24
0.82×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
NOMD
NOMD
Operating Cash FlowLast quarter
$-2.9M
$357.2M
Free Cash FlowOCF − Capex
$-6.0M
$272.4M
FCF MarginFCF / Revenue
-0.6%
32.6%
Capex IntensityCapex / Revenue
0.3%
10.2%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$1.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
NOMD
NOMD
Q4 25
$-2.9M
$357.2M
Q3 25
$10.0M
Q2 25
$90.9M
Q1 25
$16.6M
Q4 24
$-10.9M
$470.2M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$6.0M
Free Cash Flow
ASTH
ASTH
NOMD
NOMD
Q4 25
$-6.0M
$272.4M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
$383.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
NOMD
NOMD
Q4 25
-0.6%
32.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
44.8%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
NOMD
NOMD
Q4 25
0.3%
10.2%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
10.1%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
NOMD
NOMD
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
8.47×
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

NOMD
NOMD

Segment breakdown not available.

Related Comparisons